|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 401 C St NE |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20002 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Minneapolis |
State | MN |
Zip Code | 55415 |
Country | USA |
|
5. Senate ID# 300856-12
|
||||||||
|
6. House ID# 377350000
|
TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Derek C. Brandt |
Date | 1/22/2019 10:27:27 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S. 92: Safe and Affordable Drugs from Canada Act
S. 469: Affordable and Safe Prescription Drug Importation Act
S. 1131/ H.R. 2439: FAIR Drug Pricing Act
S. 1348: SPIKE Act of 2017
S. 1369/ H.R. 2974: Stop Price Gouging Act
S. 1803/H.R. 4825, the Marijuana Effective Drug Studies (MEDS) Act
S. 2076/H.R. 4256: BOLD Infrastructure for Alzheimer's Act
S. 2406: Advancing Cutting Edge (ACE) Research Act
S. 2478: End Taxpayer Subsidies for Drug Ads Act
S. 2680: Opioid Crisis Response Act
S. 2891: Fighting the Opioid Epidemic with Sunshine Act
S. 3369/ HR 6689: Ensuring Lasting Smiles Act
S. 3411/H.R. 6689: Affordable Medications Act
S. 3657/ H.R. 6615: Traumatic Brain Injury Program Reauthorization Act
S. 3686/ H.R. 3580: Protecting Student Athletes from Concussions Act
H.R. 6: SUPPORT for Patients and Communities Act: Sections 6062 and 6111; Subtitle E
H.R. 1776: Improving Access to Affordable Prescription Drugs Act
H.R. 2077: Restoring the Patient's Voice Act
H.R. 3391, Medical Marijuana Research Act of 2017
H.R. 4116: Transparent Drug Pricing Act
H.R. 5634: Medical Cannabis Research Act
H.R. 6340: Capping Prescription Costs Act
Disclosure of drug prices in prescription drug direct-to-consumer advertising; Sustained fetal tissue research; Orphan Drug Act Reform; Interoperability, including for Qualified Clinical Data Registries; NIH funding including the BRAIN Initiative; Congressionally-Directed Medical Research Program funding; concussion related issues; loan repayment for pediatric specialists.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derek |
Brandt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S. 1688: Empowering Medicare Seniors to Negotiate Drug Prices Act
S. 2908: Legislation to improve electronic prior authorization use in Medicare Advantage
S. 2051/H.R. 4206: Medicare Care Coordination Improvement Act
H.R. 4841: Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Qualified clinical data registries (QCDR) measure licensing; Step Therapy in Medicare Advantage; CMS proposed rule altering Evaluation and Management billing codes; appropriate use criteria for imaging services; CDC Neurological Conditions Surveillance System funding; Medicare coverage of oxygen therapy for cluster headaches.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derek |
Brandt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Strengthening the VA Centers of Excellence
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derek |
Brandt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 88; Section 505: Repeal of Unrelated Business Income Tax on Qualified Transportation Fringe Benefits
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Derek |
Brandt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |